How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
General Anaesthetics Market
- By Drug Type: Inhalational Anaesthetics, Intravenous Anaesthetics, Adjunct Anaesthetics
- By Application: Surgical Anaesthesia, Diagnostic Procedures, Pain Management
- By End User: Hospitals, Ambulatory Surgical Centers, Dental Clinics
- By Drug Class: Halogenated Ethers, Barbiturates, Benzodiazepines, Opioids, Propofol
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Inhalational Anaesthetics leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 268 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.161 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.169 →
Full report · locked preview
Everything inside the General Anaesthetics Market report
A complete, evidence-based study - 11 chapters and 112 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
By Drug Type 3
By Application 3
By End User 3
By Drug Class 5
Companies profiled
AbbVie Inc.
Baxter International Inc.
Fresenius Kabi
B. Braun Melsungen AG
Mylan N.V. (now part of Viatris)
Hikma Pharmaceuticals PLC
Pfizer Inc.
Mitsubishi Tanabe Pharma Corporation
Sandoz International GmbH (a Novartis division)
Lundbeck A/S
Aceto Corporation
Boehringer Ingelheim GmbH
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Fresenius Kabi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mylan N.V. (now part of Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Hikma Pharmaceuticals PLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sandoz International GmbH (a Novartis division)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Lundbeck A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Aceto Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Boehringer Ingelheim GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Hospira (a Pfizer company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Jiangsu Hengrui Medicine Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Teva Pharmaceutical Industries Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,941M by 2033 · 6.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Inhalational Anaesthetics58.1
- Intravenous Anaesthetics22.3
- Adjunct Anaesthetics19.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$387.5M → $715.1M · 8.0%
Europe$270.1M → $444.5M · 6.4%
Asia Pacific$246.6M → $441.4M · 7.5%
Latin America$152.7M → $246.1M · 6.2%
Middle East and Africa$117.4M → $211.3M · 7.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.442026
6.452027
6.462028
6.462029
6.492030
6.482031
6.502032
6.522033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- AbbVie Inc.21.1
- Baxter International Inc.21.0
- Fresenius Kabi4.2
- B. Braun Melsungen AG8.0
- Mylan N.V. (now part of Viatris)10.9
- Hikma Pharmaceuticals PLC6.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →By Drug Type22.6%
By Application22.0%
By End User29.1%
By Drug Class26.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe21.6
- Asia Pacific21.4
- Latin America12.0
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 88 | 86 | 98 | 82 | 82 | 78 | 86 |
| Baxter International Inc. | 81 | 76 | 70 | 88 | 77 | 83 | 79 |
| Fresenius Kabi | 76 | 79 | 77 | 66 | 64 | 79 | 74 |
| B. Braun Melsungen AG | 65 | 70 | 60 | 80 | 75 | 57 | 68 |
| Mylan N.V. (now part of Viatris) | 59 | 58 | 57 | 59 | 54 | 53 | 57 |
| Hikma Pharmaceuticals PLC | 63 | 57 | 49 | 66 | 61 | 60 | 59 |
| Pfizer Inc. | 49 | 48 | 64 | 52 | 40 | 63 | 53 |
| Mitsubishi Tanabe Pharma Corporation | 43 | 48 | 49 | 38 | 42 | 40 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- AbbVie Inc.
- Baxter International Inc.
- Fresenius Kabi
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| AbbVie Inc. | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Baxter International Inc. | ✓ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Fresenius Kabi | ✓ | ✓ | ◐ | ◐ | − | ✓ |
| B. Braun Melsungen AG | ◐ | ◐ | − | ◐ | ◐ | − |
| Mylan N.V. (now part of Viatris) | − | ◐ | ◐ | ◐ | ◐ | − |
| Hikma Pharmaceuticals PLC | ◐ | − | − | ◐ | ◐ | ◐ |
| Pfizer Inc. | − | ◐ | − | − | − | − |
| Mitsubishi Tanabe Pharma Corporation | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1AbbVie Inc.86
2Baxter International Inc.79
3Fresenius Kabi74
4B. Braun Melsungen AG68
5Hikma Pharmaceuticals PLC59
6Mylan N.V. (now part of Viatris)57
7Pfizer Inc.53
8Mitsubishi Tanabe Pharma Corporation43
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
AbbVie Inc.Baxter International Inc.
Challenger2
Strong scale, closing on the leaders.
Fresenius KabiB. Braun Melsungen AG
Contender2
Focused players with pockets of strength.
Mylan N.V. (now part of Viatris)Hikma Pharmaceuticals PLC
Niche2
Specialists in a single segment or region.
Pfizer Inc.Mitsubishi Tanabe Pharma Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land By Drug Type in North America, then scale across General Anaesthetics Market — a $214M beachhead inside a $3.30B market.
Beachhead (SOM)$214Mobtainable near-term
Serviceable (SAM)$1.36Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Inhalational Anaesthetics
Best fit — highest urgency & budget in By Drug Type.
Economic buyer80 fit
Intravenous Anaesthetics
Strong fit — clear ROI and a fast path to value.
End user68 fit
Adjunct Anaesthetics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win By Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add By Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + By End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For By Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win General Anaesthetics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified25%
Evaluation13%
Closed-won7%
$8.2KCAC
$31KLTV
3.8:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
General Anaesthetics Market is a resilient opportunity — $4.62B by 2033, compounding at 3.8%.
TAM · 2025$3.42Btoday
TAM · 2033$4.62Bforecast
CAGR3.8%2027–2033
Cumulative$35.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.62BTotal addressable market
SAM$1.94BServiceable available market
SOM$405MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.8% CAGR
Demand compounds through 2033, outpacing GDP across By Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in By Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.62BLarge & growingTAM by 2033 at 3.8% CAGR
$1.94BServiceable nowreachable with today’s model
$405MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.60BBear2.5% CAGR
$4.62BBase3.8% CAGR
$5.91BBull5.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & By Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
General Anaesthetics Market — a $8.12B market by 2033. Plan: grow share from 6.9% to 14.6%.
Market size · 2033$8.12Btotal addressable
Market CAGR7.7%2027–2033
Target share14.6%from 6.9% today
Revenue ambition$1.19Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.9% | 14.6% | Behind |
| Revenue | $508M | $1.19B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 28.5% | 38.8% | At risk |
| Customer retention | 90.5% | 97.0% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in By Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build By Application capability
A defensible second engine — invest in By Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core By Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch By Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $138M capacity & capability investment
- Greenlight bolt-on M&A in By Application
- Authorise North America expansion plan
- Fund R&D program for By Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the General Anaesthetics Market conversation — a $3.95B market you can size, segment and defend in minutes.
Market size · 2033$3.95Btotal opportunity
Growth8.1%CAGR to 2033
Addressable buyers1,531+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of By Drug Type
Goal Grow share in By Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 2 mopayback period
$62K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
AbbVie Inc.Baxter International Inc.Fresenius KabiB. Braun Melsungen AGMylan N.V. (now part of Viatris)Hikma Pharmaceuticals PLCPfizer Inc.Mitsubishi Tanabe Pharma Corporation+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your General Anaesthetics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
General Anaesthetics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →General Anaesthetic Medication Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportGene Prediction Tool Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportGene Mutation Detection Kit Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportGene Gun Biolistic Particle Delivery System Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportGene Fragment Synthesis Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportGene Fragment Market
Gene Fragment Market is valued at USD 842 Million in 2025 and is expected to reach USD 1.47 Bil…
$842M market · 2025 base year
View reportGene Expression System Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportGene Expression Software Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportGene Expression Screening Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportGene Expression Microarray Platform Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportGene Expression Chip Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportGene Expression and Transcriptome Sequencing Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.